The ability of FXI inhibitors to replace DOACs in atrial fibrillation for example will require at the very least similar efficacy and superior safety in patients at moderate (or high) risk for both cardioembolic stroke and major bleeding. The gene discussed is F11; the disease is cardioembolic stroke.